Altimmune completes enrollment for Phase 2 trial in AUD study

Altimmune completes enrollment for Phase 2 trial in AUD study
@AltimmuneInc: Altimmune completes trial enrollment

Altimmune has announced the completion of enrollment for its RECLAIM Phase 2 trial focused on alcohol use disorder (AUD).

This marks a significant step forward in advancing their research in this crucial area of public health. The company has expressed eagerness to continue progressing with the study and aims to share topline data from the trial by 2026. Such trials are essential in understanding and developing new treatments for alcohol use disorder, which affects millions worldwide.

The RECLAIM trial represents a part of Altimmune's broader commitment to innovative medical solutions.

Altimmune’s progress in developing treatments for alcohol use disorder underscores its active role in shaping the future of metabolic and liver health therapies. This continued commitment reflects themes discussed in the company’s collaboration with industry experts to examine the evolving MASH landscape, as explored in recent analyses of emerging approaches and challenges within the sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.